Literature DB >> 23985897

RNA expression profiling in brains of familial hemiplegic migraine type 1 knock-in mice.

Boukje de Vries1, Else Eising, Ludo A M Broos, Stephany C Koelewijn, Boyan Todorov, Rune R Frants, Judith M Boer, Michel D Ferrari, Peter A C 't Hoen, Arn M J M van den Maagdenberg.   

Abstract

BACKGROUND: Various CACNA1A missense mutations cause familial hemiplegic migraine type 1 (FHM1), a rare monogenic subtype of migraine with aura. FHM1 mutation R192Q is associated with pure hemiplegic migraine, whereas the S218L mutation causes hemiplegic migraine, cerebellar ataxia, seizures, and mild head trauma-induced brain edema. Transgenic knock-in (KI) migraine mouse models were generated that carried either the FHM1 R192Q or the S218L mutation and were shown to exhibit increased CaV2.1 channel activity. Here we investigated their cerebellar and caudal cortical transcriptome.
METHODS: Caudal cortical and cerebellar RNA expression profiles from mutant and wild-type mice were studied using microarrays. Respective brain regions were selected based on their relevance to migraine aura and ataxia. Relevant expression changes were further investigated at RNA and protein level by quantitative polymerase chain reaction (qPCR) and/or immunohistochemistry, respectively.
RESULTS: Expression differences in the cerebellum were most pronounced in S218L mice. Particularly, tyrosine hydroxylase, a marker of delayed cerebellar maturation, appeared strongly upregulated in S218L cerebella. In contrast, only minimal expression differences were observed in the caudal cortex of either mutant mice strain.
CONCLUSION: Despite pronounced consequences of migraine gene mutations at the neurobiological level, changes in cortical RNA expression in FHM1 migraine mice compared to wild-type are modest. In contrast, pronounced RNA expression changes are seen in the cerebellum of S218L mice and may explain their cerebellar ataxia phenotype.

Entities:  

Keywords:  CaV2.1 channel; FHM; cerebellum; cortex; gene expression; microarray; mutation

Mesh:

Substances:

Year:  2013        PMID: 23985897     DOI: 10.1177/0333102413502736

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  4 in total

Review 1.  Role of Omics in Migraine Research and Management: A Narrative Review.

Authors:  Pragya Chaturvedi; Rahul Khan; Prachi Sahu; Abhilash Ludhiadch; Gagandeep Singh; Anjana Munshi
Journal:  Mol Neurobiol       Date:  2022-07-07       Impact factor: 5.682

2.  Gene co-expression analysis identifies brain regions and cell types involved in migraine pathophysiology: a GWAS-based study using the Allen Human Brain Atlas.

Authors:  Else Eising; Sjoerd M H Huisman; Ahmed Mahfouz; Lisanne S Vijfhuizen; Verneri Anttila; Bendik S Winsvold; Tobias Kurth; M Arfan Ikram; Tobias Freilinger; Jaakko Kaprio; Dorret I Boomsma; Cornelia M van Duijn; Marjo-Riitta R Järvelin; John-Anker Zwart; Lydia Quaye; David P Strachan; Christian Kubisch; Martin Dichgans; George Davey Smith; Kari Stefansson; Aarno Palotie; Daniel I Chasman; Michel D Ferrari; Gisela M Terwindt; Boukje de Vries; Dale R Nyholt; Boudewijn P F Lelieveldt; Arn M J M van den Maagdenberg; Marcel J T Reinders
Journal:  Hum Genet       Date:  2016-02-22       Impact factor: 4.132

3.  Drosophila CaV2 channels harboring human migraine mutations cause synapse hyperexcitability that can be suppressed by inhibition of a Ca2+ store release pathway.

Authors:  Douglas J Brusich; Ashlyn M Spring; Thomas D James; Catherine J Yeates; Timothy H Helms; C Andrew Frank
Journal:  PLoS Genet       Date:  2018-08-06       Impact factor: 5.917

4.  Cortical Spreading Depression Causes Unique Dysregulation of Inflammatory Pathways in a Transgenic Mouse Model of Migraine.

Authors:  Else Eising; Reinald Shyti; Peter A C 't Hoen; Lisanne S Vijfhuizen; Sjoerd M H Huisman; Ludo A M Broos; Ahmed Mahfouz; Marcel J T Reinders; Michel D Ferrari; Else A Tolner; Boukje de Vries; Arn M J M van den Maagdenberg
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.